Report: Target Product Profiles: Physician Insights on Key Attributes - Pancreatic Cancer (Advanced), An emerging therapy that improves median overall survival better than the gemcitabine plus erlotinib regimen for the treatment of advanced pancreatic cancer TOC

Target Product Profiles: Physician Insights on Key Attributes - Pancreatic Cancer (Advanced), An emerging therapy that improves median overall survival better than the gemcitabine plus erlotinib regimen for the treatment of advanced pancreatic cancer

Published by

Decision Resources, Inc.

Published

2008/03

Content info

41 Pages

Product code

DR65871

Price

From US $ 5625

PDF by E-Mail

Approx. 1-2 business days

Hard Copy/CD-ROM

Approx. 3-4 business days

If you need expedited delivery, please call us.

Introduction
- Using Target Product Profiles in Your Market Strategy
- Report Contents
- Target Product Profile Methodology
Etiology and Pathophysiology
- Overview
- Anatomy
- Etiology
  - Oncogenes
  - Tumor Suppressor Genes
  - Genome Maintenance Genes
  - Epidermal Growth Factors and Epidermal Growth Factor Receptors
  - Vascular Endothelial Growth Factor
  - Signaling Pathways
  - Other Factors in PC
  - Risk Factors
- Pathophysiology
  - Staging
  - Prognosis
Target Product Profile Discussion-Advanced Pancreatic Cancer
- Target Product Profile Summary for Advanced Pancreatic Cancer-2011
- Assessing Drug Development Opportunities
- Physician Survey Results
  - Effi cacy
  - Safety and Tolerability
  - Delivery
  - Estimated Patient Share
- Pricing Potential
- Forecasted 2016 Pricing Environment
- Competitors to Watch
- Emerging Product Profiles

Target Product Profiles: Physician Insights on Key Attributes - Pancreatic Cancer (Advanced), An emerging therapy that improves median overall survival better than the gemcitabine plus erlotinib regimen for the treatment of advanced pancreatic cancer

Table of Contents